This chapter gives an overview of the origins, chemistry, composition and production of Fluosol-DA (later Fluosol®), and describes preclinical and clinical studies with the emulsion that led to its regulatory approval as an oxygen-carrying fluid and adjunct to coronary angioplasty.

The first approved oxygen-carrying blood substitute was a per fluorocarbon -based product called Fluosol -DA-20, manufactured by Green Cross of Japan. It was approved by the Food and Drug Administration (FDA) in 1989. Because of limited success, complexity of use and side effects, it was withdrawn in 1994.

2024年2月9日 · Fluosol-DA是全氟烃和全氟三丙胺作为主要活性成分，与Pluronic F-68乳化而成的一种血红蛋白替代品。 由日本的Green Cross Corporation和美国加利福尼亚州洛杉矶的Alpha Therapeutics共同制造，该产品于几十年前获得了FDA的批准，用于经皮经腔冠状动脉成形术。

Fluosol (20% intravascular perfluorochemical emulsion) is an oxygen-carrying emulsion used to deliver oxygen to ischemic myocardium during percutaneous transluminal coronary angioplasty (PTCA). Fluosol is composed of two perfluorochemicals, perfluorodecalin and perfluorotripropylamine.

We assessed the safety and efficacy of Fluosol-DA as a red-cell substitute in acute anemia. Twenty-three surgical patients with blood loss and religious objections to receiving blood...

We evaluated the safety and efficacy of Fluosol DA-20% (FDA) as a blood substitute in the treatment of severe anemia. Thirty-six patients received either FDA (n = 21) or crystalloid/hydroxyethyl starch (CHS) (n = 15) as part of a randomized, controlled trial. Ten patients received FDA as part of a h …

2006年12月31日 · Fluosol was the first injectable oxygen carrier approved by the US FDA for clinical use. As a result, extensive preclinical and clinical data are available for review, and much of the...

After the experimental and phase one studies of our so-called "artificial blood," Fluosol-DA (20%), an emulsified mixture of perfluorodecalin and perfluorotripropylamine, were successfully completed, phase two and three clinical studies were carried ...

Fluosol-DA is a perfluorocarbon blood substitute in trials for the treatment of severe anemia. 1,1,2,2,3,3,4,4,4 a,5,5,6,6,7,7,8,8,8 a -octadecafluoronaphthalene;4- (2-aminoethyl)benzene-1,2-diol.

The approval of Fluosol, a fluorocarbon emulsion for oxygenating the myocardium during the transluminal coronary angioplasty procedure, is a landmark in the field of injectable oxygen carriers, the so-called blood substitutes. This review discusses the advances made since this first emulsion was ini …